NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023 :  Featured Updates to the NCCN Guidelines

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Novel targeted therapies (small molecule inhibitors, antibody–drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton’s tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. Anti-CD19 CAR T-cell therapies are now effective and approved treatment options for relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and MCL. Bispecific T-cell engagers represent a novel immunotherapeutic approach for relapsed FL and DLBCL after multiple lines of therapies, including prior CAR T-cell therapy. These NCCN Guideline Insights highlight the significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, DLBCL, and MCL.

Related collections

Most cited references 86

Record: found
Abstract: found
Article: found

Is Open Access

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Daniel W. Lee, Bianca D. Santomasso, Frederick L. Locke … (2019)

Chimeric antigen receptor (CAR) T cell therapy is rapidly emerging as one of the most promising therapies for hematologic malignancies. Two CAR T products were recently approved in the United States and Europe for the treatment ofpatients up to age 25years with relapsed or refractory B cell acute lymphoblastic leukemia and/or adults with large B cell lymphoma. Many more CAR T products, as well as other immunotherapies, including various immune cell- and bi-specific antibody-based approaches that function by activation of immune effector cells, are in clinical development for both hematologic and solid tumor malignancies. These therapies are associated with unique toxicities of cytokine release syndrome (CRS) and neurologic toxicity. The assessment and grading of these toxicities vary considerably across clinical trials and across institutions, making it difficult to compare the safety of different products and hindering the ability to develop optimal strategies for management of these toxicities. Moreover, some aspects of these grading systems can be challenging to implement across centers. Therefore, in an effort to harmonize the definitions and grading systems for CRS and neurotoxicity, experts from all aspects of the field met on June 20 and 21, 2018, at a meeting supported by the American Society for Transplantation and Cellular Therapy (ASTCT; formerly American Society for Blood and Marrow Transplantation, ASBMT) in Arlington, VA. Here we report the consensus recommendations of that group and propose new definitions and grading for CRS and neurotoxicity that are objective, easy to apply, and ultimately more accurately categorize the severity of these toxicities. The goal is to provide a uniform consensus grading system for CRS and neurotoxicity associated with immune effector cell therapies, for use across clinical trials and in the postapproval clinical setting.

0 comments Cited 1016 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Jeremy S. Abramson, M. Palomba, Leo I Gordon … (2020)

Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric antigen receptor (CAR) T-cell product. We aimed to assess the activity and safety of liso-cel in patients with relapsed or refractory large B-cell lymphomas.

0 comments Cited 842 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

Sattva Neelapu, Sudhakar Tummala, Partow Kebriaei … (2018)

Chimeric antigen receptor (CAR)-T-cell therapies are showing great promise in the treatment of cancer, particularly B-cell malignancies, but are associated with characteristic, potentially fatal toxicities, principally cytokine-release syndrome, CAR-T-cell-related encephalopathy syndrome, and haemophagocytic lymphohistiocytosis/macrophage-activation syndrome. Herein, the CAR-T-cell-therapy-associated TOXicity (CARTOX) Working Group, comprising multidisciplinary investigators from various institutions with clinical experience in the use of a range of CAR-T-cell platforms, review these acute toxicities and provide monitoring, grading, and management recommendations.

0 comments Cited 724 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Title: Journal of the National Comprehensive Cancer Network

Publisher: Harborside Press, LLC

ISSN (Print): 1540-1405

ISSN (Electronic): 1540-1413

Publication date Created: November 2023

Publication date (Print): November 2023

Volume: 21

Issue: 11

Pages: 1118-1131

Affiliations

[1 ]Memorial Sloan Kettering Cancer Center

[2 ]Robert H. Lurie Comprehensive Cancer Center of Northwestern University

[3 ]Massachusetts General Hospital Cancer Center

[4 ]Stanford Cancer Institute

[5 ]UCSF Helen Diller Family Comprehensive Cancer Center

[6 ]Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

[7 ]City of Hope National Medical Center

[8 ]Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

[9 ]University of Wisconsin Carbone Cancer Center

[10 ]The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

[11 ]UCLA Jonsson Comprehensive Cancer Center

[12 ]Vanderbilt-Ingram Cancer Center

[13 ]The University of Texas MD Anderson Cancer Center

[14 ]Mayo Clinic Comprehensive Cancer Center

[15 ]St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center

[16 ]Roswell Park Comprehensive Cancer Center

[17 ]Huntsman Cancer Institute at the University of Utah

[18 ]University of Michigan Rogel Cancer Center

[19 ]Duke Cancer Institute

[20 ]Consultant

[21 ]Dana-Farber/Brigham and Women’s Cancer Center

[22 ]Fox Chase Cancer Center

[23 ]O’Neal Comprehensive Cancer Center at UAB

[24 ]University of Colorado Cancer Center

[25 ]UT Southwestern Simmons Comprehensive Cancer Center

[26 ]UC San Diego Moores Cancer Center

[27 ]Yale Cancer Center/Smilow Cancer Hospital

[28 ]Moffitt Cancer Center

[29 ]Fred Hutchinson Cancer Center

[30 ]Abramson Cancer Center at the University of Pennsylvania

[31 ]The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

[32 ]UC Davis Comprehensive Cancer Center

[33 ]Fred & Pamela Buffett Cancer Center

[34 ]National Comprehensive Cancer Network

Article

DOI: 10.6004/jnccn.2023.0057

SO-VID: 64e1b77b-68a9-45f9-937b-ac077ae171f3

History

Data availability:

Comments

Comment on this article

scite_

Cited by 4

See all cited by

Most referenced authors 1,786

See all reference authors

- Version 1

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023 : Featured Updates to the NCCN Guidelines

Read this article at

Abstract

Related collections

Preventive and Emergency Medicine Insights

Most cited references 86

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 968

Cited by 4

Most referenced authors 1,786